RE:RE:RE:Shure hope they avoid another OO at these levelsThis really is the case as far as raising money. I guess I would hope that if the restart of trail and some of the first 6 patients show low SAE, some SD, that I'd be fine with them selling $10-20mil at a $1.50 to $2 range to provide a bit of flexibility and given the small size, not selling the ranch. That at least woudl replenish the coffers to give them time for Plan A or B depending on what the ultimate results are. I look at it as those shares were sold already as warrants at $3, so it was already seen as future dilution, it just never got there.
Points out that they really should be running very strong on trying to find someone to partner on either the IO combo findings to share that business line and to develop a trial specific to the PD-L1 guys, and maybe even the carboplatin combo trial.
One other thing I thought about with those pretty amazing results that Dr. winer pointed out --the very long SD and a patient of his that continued SD despite not taking the drug anymore, is that the maybe the stem cell and VM disruption is truly a pretty powerful anti-metastatic prescription for some period of time and it somehow becomes self-reinforcing if you eliminate a certain amount. I really don't know. But may point out there is a large value in studying the anti-metastatic use as a pre and post treatment to any other standard oncology therapy. That's what they showed in the mouse lung study. Would be very helpful for TNBC and such.